Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 8 clients • 12 examiners • 9 art units • 0 of 12 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
PERKINS COIE LLP - LOS GENERAL manages 1928 career applications in the Biotechnology & Pharmaceuticals technology area. The firm has a resolved allowance rate of 75.87 percent. Prosecution involves an average of 3.53 office actions per allowance. There are 13 pending office actions currently active.
This workload is part of the firm's history with 1928 career applications. The 75.87 percent resolved allowance rate is a metric for the firm's performance in Biotechnology & Pharmaceuticals. The 3.53 average office actions per allowance indicates the effort required to secure these grants. This firm's data demonstrates a practice with a volume of 1928 career applications. The 75.87 percent resolved allowance rate provides a baseline for performance. With 13 pending office actions, the firm is managing its current docket in its primary technology area, using a prosecution style that averages 3.53 office actions per grant. The 3.53 average office actions per allowance is a consistent factor in its 1928 career applications.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 3 (25%) |
| §102 only | 1 (8%) |
| §112 only | 1 (8%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 5 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, JULIA C | 1 | 62.5% | +31.9% |
| SABOURI, MAZDA | 1 | 77.2% | +17.0% |
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
| HADEN, SALLY CLINE | 1 | 32.0% | +41.6% |
| ALMATRAHI, SAHAR FARIS | 1 | 30.3% | +56.9% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 66.7% | +0.0% |
| MEYERING, SHABANA SHABBEER | 1 | 70.6% | +42.3% |
| FORD, VANESSA L | 1 | 38.3% | +38.4% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 29d |
| 18823633 | DUAL-DIRECTION TILLER/CULTIVATOR | TRAN, JULIA C | — |
| 18557406 | MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF | CORNELIUS, CLAIRE ADRIENNE | — |
| 18554286 | CANCER TREATMENT BY TARGETING PROTEINS OR INTERACTIONS OF EPHRINB-RGS3-KIF20A-SEPT7 AXIS | MEYERING, SHABANA SHABBEER | — |
| 18251871 | THERAPEUTIC TARGETING OF MESOTHELIN IN ACUTE MYELOID LEUKEMIA WITH CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | HOWARD, ZACHARY C | — |
| 16968504 | PROMOTING AND PROTECTING FUNCTIONAL BETA CELL MASS BY SYNTAXIN 4 ENRICHMENT | CONNORS, ALEXANDRA F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999352 | ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF | CUNNINGCHEN, KATHLEEN MARY | 88d overdue |
| 18750401 | MOBILITY ENFORCEMENT IN CONNECTED WIRELESS STATE | SABOURI, MAZDA | 6d |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 29d |
| 18270706 | PREVENTION AND TREATMENT OF STEROID-RESISTANT OR GUT GRAFT-VERSUS-HOST DISEASE (GVHD) | FORD, VANESSA L | 40d |
| 18823633 | DUAL-DIRECTION TILLER/CULTIVATOR | TRAN, JULIA C | — |
| 18648238 | GLOVE WITH STRUCTURAL FINGER REINFORCEMENTS | HADEN, SALLY CLINE | — |
| 18529891 | VARIABLE-VOLUME CONE FOR RESTRAINING BIRDS | ALMATRAHI, SAHAR FARIS | — |
| 18554286 | CANCER TREATMENT BY TARGETING PROTEINS OR INTERACTIONS OF EPHRINB-RGS3-KIF20A-SEPT7 AXIS | MEYERING, SHABANA SHABBEER | — |
| Client (Assignee) | Pending OAs |
|---|---|
| City of Hope | 3 |
| Ardisam, Inc. | 2 |
| Fred Hutchinson Cancer Research Center | 2 |
| ZTE | 1 |
| Rawlings | 1 |
| Ciy Of Hope | 1 |
| University of California | 1 |
| SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION | 1 |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| 1674 | 2 |
| 2641 | 1 |
| 3732 | 1 |
| 3643 | 1 |
| 1672 | 1 |
| 1646 | 1 |
| 1634 | 1 |
| 1658 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18823633 | DUAL-DIRECTION TILLER/CULTIVATOR | Ardisam, Inc. | TRAN, JULIA C | §102§103Other | Non-Final OA | — | Pending | Sep 03, 2024 | |
| 18750401 | MOBILITY ENFORCEMENT IN CONNECTED WIRELESS STATE | ZTE CORPORATION | SABOURI, MAZDA | 2641 | §103 | Final Rejection | 6d | Pending | Jun 21, 2024 |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | City Of Hope | GIBBS, TERRA C | 1635 | §102§103 | Non-Final OA | 29d | Pending | May 02, 2024 |
| 18648238 | GLOVE WITH STRUCTURAL FINGER REINFORCEMENTS | Rawlings Sporting Goods Company, Inc. | HADEN, SALLY CLINE | 3732 | §102 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18529891 | VARIABLE-VOLUME CONE FOR RESTRAINING BIRDS | Ardisam, Inc. | ALMATRAHI, SAHAR FARIS | 3643 | §103 | Final Rejection | — | Pending | Dec 05, 2023 |
| 18557406 | MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF | Fred Hutchinson Cancer Center | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§103§112 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18554286 | CANCER TREATMENT BY TARGETING PROTEINS OR INTERACTIONS OF EPHRINB-RGS3-KIF20A-SEPT7 AXIS | City Of Hope | MEYERING, SHABANA SHABBEER | 1635 | §102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18270706 | PREVENTION AND TREATMENT OF STEROID-RESISTANT OR GUT GRAFT-VERSUS-HOST DISEASE (GVHD) | Ciy Of Hope | FORD, VANESSA L | 1674 | §112 | Non-Final OA | 40d | Pending | Jun 30, 2023 |
| 18251871 | THERAPEUTIC TARGETING OF MESOTHELIN IN ACUTE MYELOID LEUKEMIA WITH CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | Fred Hutchinson Cancer Center | HOWARD, ZACHARY C | 1674 | §103§112 | Final Rejection | — | Pending | May 04, 2023 |
| 17999352 | ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF | The Regents of the University of California | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103§112DP | Final Rejection | 88d overdue | Pending | Nov 18, 2022 |
| 16968504 | PROMOTING AND PROTECTING FUNCTIONAL BETA CELL MASS BY SYNTAXIN 4 ENRICHMENT | City Of Hope | CONNORS, ALEXANDRA F | 1634 | §103§112 | Non-Final OA | — | Pending | Aug 07, 2020 |
| 15045068 | STABLE AQUEOUS PARENTERAL PHARMACEUTICAL COMPOSITIONS OF INSULINOTROPIC PEPTIDES | Shanghai Benemae Pharmaceutical Corporation | KOMATSU, LI N | 1658 | §103 | Final Rejection | 86d overdue | Pending | Feb 16, 2016 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial